Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Today, however, we are actually daydreaming about an upcoming week-long break in which we plan to spend time indulging a couple of our short people and gallivanting with Mrs. Pharmalot. You can still reach us by e-mail, though, if you wish. But what about you? What will you do this weekend? Spring has sprung, so perhaps you can enjoy the great outdoors or prepare for a garage sale. You could also take stock of the world, such as it is, or simply tune it out. Well, whatever you do, have a grand time. But be safe. Enjoy, and you soon …

The European Medicines Agency decided that an Actelion drug called Uptravi can continue to be used by new and existing patients following a review sparked by five patient deaths in France. The agency concluded that the data do not suggest any increase in mortality and that patient death rates are in line with observations for other pulmonary arterial hypertension medicines. Johnson & Johnson is buying Actelion for $30 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!